![]() |
加州圣荷西2018年5月9日電 /美通社/ -- 值得信賴的先進材料創新合作伙伴Intermolecular, Inc. (NASDAQ: IMI)今天發布截至2018年3月31日的(de)第(di)一季度業績(ji)。
2018年第一季度財務與運營業績亮點:
管理層評論
該公司總裁兼首席執行(xing)官(guan)Chris Kramer表(biao)示:“2018年(nian)第(di)一(yi)季度(du)是Intermolecular連續(xu)第(di)三(san)季度(du)實現積極(ji)的(de)調(diao)整(zheng)后(hou)EBITDA,這(zhe)是2013年(nian)以來(lai)的(de)首次。我(wo)(wo)(wo)們(men)財務業績的(de)改(gai)善得益于我(wo)(wo)(wo)們(men)過去一(yi)年(nian)采取的(de)行(xing)動,既(ji)增加了(le)客戶的(de)參與(yu),又(you)減(jian)少了(le)我(wo)(wo)(wo)們(men)的(de)成本結(jie)構。具體(ti)來(lai)說,本季度(du)我(wo)(wo)(wo)們(men)的(de)項目(mu)服務收入同比增加了(le)240萬(wan)(wan)美(mei)元,增幅為36%,而運營費用(yong)減(jian)少了(le)450萬(wan)(wan)美(mei)元。這(zhe)些優勢大大抵消了(le)傳統項目(mu)的(de)版(ban)稅計劃到期的(de)影響,也是實現可(ke)持續(xu)盈(ying)利能(neng)(neng)力(li)的(de)關鍵。我(wo)(wo)(wo)們(men)與(yu)新老客戶的(de)合作不斷擴大,我(wo)(wo)(wo)們(men)仍然(ran)相信我(wo)(wo)(wo)們(men)有(you)能(neng)(neng)力(li)繼續(xu)增長和擴大我(wo)(wo)(wo)們(men)的(de)業務利潤。
2018財年第一季度業績
2018年(nian)(nian)(nian)第一季(ji)度(du)(du)(du)營收(shou)(shou)為970萬美元(yuan)(yuan),較(jiao)2017年(nian)(nian)(nian)第四季(ji)度(du)(du)(du)的(de)1050萬美元(yuan)(yuan)下(xia)降了8%,較(jiao)上年(nian)(nian)(nian)同期的(de)990萬美元(yuan)(yuan)下(xia)降3%。項(xiang)目營收(shou)(shou)為930萬美元(yuan)(yuan),較(jiao)上季(ji)度(du)(du)(du)增(zeng)長(chang)5%,較(jiao)上年(nian)(nian)(nian)同期增(zeng)長(chang)36%。
2018年(nian)第一季度(du)的凈虧損(sun)(sun)為60萬(wan)(wan)美(mei)元(yuan)(合(he)每股(gu)(gu)虧損(sun)(sun)0.01美(mei)元(yuan)),而2017年(nian)第四季度(du)的凈盈余為10萬(wan)(wan)美(mei)元(yuan)(合(he)每股(gu)(gu)虧損(sun)(sun)0.00美(mei)元(yuan)),上年(nian)同(tong)期凈虧損(sun)(sun)則為580萬(wan)(wan)美(mei)元(yuan)(合(he)每股(gu)(gu)虧損(sun)(sun)0.12美(mei)元(yuan))。
2018年(nian)第一季(ji)度(du)非GAAP(公認會計準(zhun)則(ze))凈虧(kui)損為40萬美元(yuan),合每(mei)(mei)股(gu)(gu)0.01美元(yuan),上(shang)季(ji)度(du)非GAAP凈盈余為40萬美元(yuan)(合每(mei)(mei)股(gu)(gu)0.01美元(yuan)),而上(shang)年(nian)同期非GAAP凈虧(kui)損520萬美元(yuan)(合每(mei)(mei)股(gu)(gu)虧(kui)損0.10美元(yuan))。
2018年第(di)一季度調整(zheng)后EBITDA為(wei)100萬(wan)美(mei)(mei)元(yuan),上(shang)季度為(wei)210萬(wan)美(mei)(mei)元(yuan),上(shang)年同期調整(zheng)后EBITDA虧損190萬(wan)美(mei)(mei)元(yuan)。
2018年第(di)一(yi)季度(du)末現金(jin)和投資為2720萬(wan)(wan)美(mei)元,較(jiao)2017年第(di)四季度(du)末的2580萬(wan)(wan)美(mei)元增(zeng)長140萬(wan)(wan)美(mei)元。該公(gong)司(si)在季度(du)末沒有債務。
2018年第二季度預測
以下陳述(shu)(shu)(shu)基于(yu)Intermolecular當前(qian)對截至2018年6月30日的第二季度的預測。以下陳述(shu)(shu)(shu)為前(qian)瞻性(xing)(xing)陳述(shu)(shu)(shu),實際結果(guo)可能會因(yin)為受(shou)到(dao)市場情況以及下文“前(qian)瞻性(xing)(xing)陳述(shu)(shu)(shu)”部分(fen)中列(lie)舉(ju)的因(yin)素的影響(xiang),而產生重大出入。Intermolecular不打算也沒有義務在(zai)以后更新此預測。
Intermolecular分別根據美國公(gong)(gong)認會計(ji)(ji)準(zhun)(zhun)則(ze)(ze)和(he)非公(gong)(gong)認會計(ji)(ji)準(zhun)(zhun)則(ze)(ze)報(bao)告了(le)營收(shou)、營收(shou)成本(ben)、毛利(li)率(lv)、經營盈余(虧(kui)損)、凈盈余(虧(kui)損)和(he)每股盈余(虧(kui)損)。本(ben)新(xin)聞稿的(de)(de)財(cai)務(wu)報(bao)表部分包含了(le)非GAAP財(cai)務(wu)衡量指(zhi)標(biao)與(yu)最直接可比的(de)(de)GAAP衡量指(zhi)標(biao)的(de)(de)對照(zhao)表,以及不包括在非GAAP指(zhi)標(biao)中的(de)(de)項(xiang)目說(shuo)明(ming)。請參(can)考下(xia)(xia)文(wen)“公(gong)(gong)認會計(ji)(ji)準(zhun)(zhun)則(ze)(ze)與(yu)非公(gong)(gong)認會計(ji)(ji)準(zhun)(zhun)則(ze)(ze)財(cai)務(wu)衡量標(biao)準(zhun)(zhun)對照(zhao)表”和(he)“公(gong)(gong)認會計(ji)(ji)準(zhun)(zhun)則(ze)(ze)下(xia)(xia)的(de)(de)凈盈余/虧(kui)損與(yu)非公(gong)(gong)認會計(ji)(ji)準(zhun)(zhun)則(ze)(ze)下(xia)(xia)的(de)(de)凈盈余對照(zhao)表”。
電話會議
Intermolecular將在(zai)美國(guo)東部時(shi)間(jian)今天(tian)(2018年5月(yue)8日)下(xia)午5:00(太平洋(yang)時(shi)間(jian)下(xia)午2:00)召開電話會議(yi)和(he)同步音頻網絡直播(bo),討論業績。會議(yi)將由Intermolecular總(zong)裁(cai)兼首席執行官(guan)Chris Kramer和(he)首席財務官(guan)Bill Roeschlein主持(chi)。
美國撥入電話:(877) 251-1860
國際撥入電話:(224) 357-2386
會(hui)議ID:2183689
請在會議(yi)開始前(qian)5到(dao)10分(fen)鐘撥打電話會議(yi)號碼。接(jie)線員會登記你的名字和單位。如(ru)在電話會議(yi)連接(jie)方面(mian)遇到(dao)問題,請聯系:Liolios Group,電話:(949) 574-2386
可在Intermolecular的查看現場直(zhi)播和(he)直(zhi)播存檔(只有音頻),保留到電話(hua)會議后30天。
Intermolecular, Inc.簡介
Intermolecular®是(shi)值得信賴(lai)的先進(jin)材料(liao)創新合(he)作伙(huo)伴。在21世紀,先進(jin)材料(liao)是(shi)多(duo)個行業領域創新的核心,包括半導體、消費(fei)電子產品(pin)、汽車和航天。憑借大量的材料(liao)專業知識(shi)、加速的學習和實踐平(ping)臺、以及信息和分析基礎設施,Intermolecular擁有(you)十年幫助領先公(gong)司加快材料(liao)創新和降低風(feng)險(xian)的經驗。詳情請訪問。
“Intermolecular”和Intermolecular的圖標為注(zhu)冊商標;保留所有權利。
前瞻性陳述
本(ben)(ben)(ben)(ben)新(xin)聞稿(gao)中(zhong)非(fei)歷史事(shi)實(shi)(shi)(shi)性的(de)(de)(de)(de)(de)陳(chen)(chen)述(shu)和(he)參(can)考了本(ben)(ben)(ben)(ben)新(xin)聞稿(gao)的(de)(de)(de)(de)(de)盈(ying)利電話會議為(wei)前(qian)(qian)(qian)瞻(zhan)性陳(chen)(chen)述(shu)。前(qian)(qian)(qian)瞻(zhan)性陳(chen)(chen)述(shu)受1995年《私人證(zheng)券訴訟(song)改革法(fa)案》中(zhong)“安全港”條款的(de)(de)(de)(de)(de)制(zhi)約(yue)。前(qian)(qian)(qian)瞻(zhan)性陳(chen)(chen)述(shu)一般可(ke)通過(guo)“將要”、“可(ke)能(neng)(neng)”、“預(yu)計(ji)”、“相信(xin)(xin)”、“計(ji)劃(hua)”、“打算”、“預(yu)測(ce)(ce)”等(deng)措辭以及(ji)其(qi)它(ta)意義(yi)相近的(de)(de)(de)(de)(de)措辭來(lai)(lai)加以辨(bian)別。我(wo)們(men)敬告投資者(zhe),本(ben)(ben)(ben)(ben)文(wen)中(zhong)的(de)(de)(de)(de)(de)前(qian)(qian)(qian)瞻(zhan)性陳(chen)(chen)述(shu)基(ji)于(yu)(yu)當(dang)前(qian)(qian)(qian)的(de)(de)(de)(de)(de)看(kan)法(fa)、假設和(he)預(yu)測(ce)(ce),僅(jin)代表(biao)本(ben)(ben)(ben)(ben)文(wen)發(fa)布時(shi)的(de)(de)(de)(de)(de)觀點,并涉及(ji)一些(xie)可(ke)能(neng)(neng)導(dao)(dao)致(zhi)(zhi)實(shi)(shi)(shi)際(ji)(ji)結(jie)果(guo)與(yu)(yu)當(dang)前(qian)(qian)(qian)預(yu)期(qi)產(chan)(chan)生(sheng)重(zhong)大(da)出入的(de)(de)(de)(de)(de)風(feng)險和(he)不(bu)確定性。這些(xie)陳(chen)(chen)述(shu)受到(dao)某些(xie)已知和(he)未知風(feng)險和(he)不(bu)確定性的(de)(de)(de)(de)(de)影(ying)響(xiang),其(qi)中(zhong)有(you)(you)很(hen)多難以預(yu)料,一般不(bu)在(zai)Intermolecular的(de)(de)(de)(de)(de)控制(zhi)范圍之(zhi)內,這可(ke)能(neng)(neng)導(dao)(dao)致(zhi)(zhi)實(shi)(shi)(shi)際(ji)(ji)結(jie)果(guo)和(he)其(qi)它(ta)未來(lai)(lai)事(shi)件與(yu)(yu)前(qian)(qian)(qian)瞻(zhan)性信(xin)(xin)息和(he)陳(chen)(chen)述(shu)中(zhong)明示(shi)或(huo)(huo)暗示(shi)或(huo)(huo)預(yu)測(ce)(ce)的(de)(de)(de)(de)(de)情況產(chan)(chan)生(sheng)重(zhong)大(da)出入。可(ke)導(dao)(dao)致(zhi)(zhi)實(shi)(shi)(shi)際(ji)(ji)結(jie)果(guo)與(yu)(yu)當(dang)前(qian)(qian)(qian)預(yu)測(ce)(ce)產(chan)(chan)生(sheng)重(zhong)大(da)出入的(de)(de)(de)(de)(de)主要因(yin)素(su)包括(kuo)(但(dan)不(bu)僅(jin)限(xian)(xian)于(yu)(yu)):該公(gong)(gong)(gong)(gong)(gong)(gong)(gong)司(si)(si)(si)與(yu)(yu)現(xian)(xian)有(you)(you)及(ji)未來(lai)(lai)客(ke)戶(hu)(hu)產(chan)(chan)品化(hua)其(qi)工作(zuo)流的(de)(de)(de)(de)(de)能(neng)(neng)力;有(you)(you)關(guan)未來(lai)(lai)營收、現(xian)(xian)金流和(he)GAAP及(ji)非(fei)GAAP凈盈(ying)余(yu)或(huo)(huo)虧損的(de)(de)(de)(de)(de)預(yu)測(ce)(ce);財務(wu)狀況;公(gong)(gong)(gong)(gong)(gong)(gong)(gong)司(si)(si)(si)新(xin)業(ye)(ye)務(wu)模式創造利潤及(ji)長(chang)期(qi)股東回(hui)報的(de)(de)(de)(de)(de)能(neng)(neng)力;與(yu)(yu)客(ke)戶(hu)(hu)合(he)作(zuo)開發(fa)的(de)(de)(de)(de)(de)技術(shu)(shu)將繼(ji)續保持(chi)關(guan)鍵路線以及(ji)對客(ke)戶(hu)(hu)、公(gong)(gong)(gong)(gong)(gong)(gong)(gong)司(si)(si)(si)和(he)整個(ge)行業(ye)(ye)具(ju)備(bei)重(zhong)要價值的(de)(de)(de)(de)(de)程(cheng)度(du);以及(ji)公(gong)(gong)(gong)(gong)(gong)(gong)(gong)司(si)(si)(si)通過(guo)拓(tuo)展現(xian)(xian)有(you)(you)客(ke)戶(hu)(hu)計(ji)劃(hua)以及(ji)與(yu)(yu)新(xin)客(ke)戶(hu)(hu)達成(cheng)其(qi)它(ta)合(he)同(tong)而在(zai)當(dang)前(qian)(qian)(qian)市場的(de)(de)(de)(de)(de)預(yu)期(qi)增長(chang)。前(qian)(qian)(qian)瞻(zhan)性陳(chen)(chen)述(shu)受到(dao)可(ke)導(dao)(dao)致(zhi)(zhi)實(shi)(shi)(shi)際(ji)(ji)結(jie)果(guo)與(yu)(yu)預(yu)期(qi)產(chan)(chan)生(sheng)重(zhong)大(da)出入的(de)(de)(de)(de)(de)風(feng)險和(he)不(bu)確定性的(de)(de)(de)(de)(de)影(ying)響(xiang),包括(kuo)(但(dan)不(bu)僅(jin)限(xian)(xian)于(yu)(yu)):公(gong)(gong)(gong)(gong)(gong)(gong)(gong)司(si)(si)(si)執(zhi)行戰(zhan)略、證(zheng)明業(ye)(ye)務(wu)模式和(he)在(zai)瞬息萬變行業(ye)(ye)環境下(xia)保持(chi)技術(shu)(shu)競(jing)爭力的(de)(de)(de)(de)(de)能(neng)(neng)力;公(gong)(gong)(gong)(gong)(gong)(gong)(gong)司(si)(si)(si)HPC平臺(tai)和(he)方法(fa)作(zuo)為(wei)有(you)(you)效(xiao)研發(fa)工具(ju)的(de)(de)(de)(de)(de)商業(ye)(ye)接受度(du);公(gong)(gong)(gong)(gong)(gong)(gong)(gong)司(si)(si)(si)取(qu)得(de)和(he)保持(chi)盈(ying)利性的(de)(de)(de)(de)(de)能(neng)(neng)力;公(gong)(gong)(gong)(gong)(gong)(gong)(gong)司(si)(si)(si)客(ke)戶(hu)(hu)及(ji)時(shi)實(shi)(shi)(shi)現(xian)(xian)其(qi)已公(gong)(gong)(gong)(gong)(gong)(gong)(gong)布產(chan)(chan)品藍圖的(de)(de)(de)(de)(de)能(neng)(neng)力;公(gong)(gong)(gong)(gong)(gong)(gong)(gong)司(si)(si)(si)能(neng)(neng)在(zai)多大(da)程(cheng)度(du)上成(cheng)功延伸和(he)拓(tuo)展與(yu)(yu)現(xian)(xian)有(you)(you)客(ke)戶(hu)(hu)的(de)(de)(de)(de)(de)關(guan)系;公(gong)(gong)(gong)(gong)(gong)(gong)(gong)司(si)(si)(si)管理(li)業(ye)(ye)務(wu)增長(chang)的(de)(de)(de)(de)(de)能(neng)(neng)力;公(gong)(gong)(gong)(gong)(gong)(gong)(gong)司(si)(si)(si)所服務(wu)的(de)(de)(de)(de)(de)客(ke)戶(hu)(hu)及(ji)行業(ye)(ye)快速的(de)(de)(de)(de)(de)技術(shu)(shu)更迭和(he)波動;公(gong)(gong)(gong)(gong)(gong)(gong)(gong)司(si)(si)(si)未來(lai)(lai)潛在(zai)的(de)(de)(de)(de)(de)資金需求,用于(yu)(yu)支持(chi)運營;以及(ji)公(gong)(gong)(gong)(gong)(gong)(gong)(gong)司(si)(si)(si)最近提交給美國證(zheng)券交易委員(yuan)會的(de)(de)(de)(de)(de)10-K表(biao)年度(du)報告(10-Q表(biao)季度(du)報告更新(xin))和(he)其(qi)它(ta)文(wen)件(可(ke)參(can)見)中(zhong)描述(shu)的(de)(de)(de)(de)(de)其(qi)它(ta)風(feng)險,尤(you)其(qi)是標題(ti)為(wei)“風(feng)險因(yin)素(su)”的(de)(de)(de)(de)(de)章節。所有(you)(you)前(qian)(qian)(qian)瞻(zhan)性陳(chen)(chen)述(shu)均基(ji)于(yu)(yu)管理(li)層當(dang)前(qian)(qian)(qian)的(de)(de)(de)(de)(de)估(gu)計(ji)、預(yu)測(ce)(ce)和(he)假設,公(gong)(gong)(gong)(gong)(gong)(gong)(gong)司(si)(si)(si)不(bu)承擔更新(xin)義(yi)務(wu)。
非公認會計準則財務衡量指標
為(wei)(wei)補充基于(yu)公(gong)(gong)(gong)(gong)認(ren)(ren)會(hui)(hui)(hui)計(ji)(ji)準(zhun)(zhun)(zhun)則(ze)(ze)(ze)的(de)(de)(de)財(cai)(cai)務(wu)(wu)(wu)數(shu)據,我(wo)(wo)(wo)們(men)(men)還公(gong)(gong)(gong)(gong)開了某(mou)些(xie)(xie)非(fei)(fei)公(gong)(gong)(gong)(gong)認(ren)(ren)會(hui)(hui)(hui)計(ji)(ji)準(zhun)(zhun)(zhun)則(ze)(ze)(ze)財(cai)(cai)務(wu)(wu)(wu)衡量(liang)(liang)指標,不包(bao)括基于(yu)股(gu)(gu)票的(de)(de)(de)薪酬(chou)(chou)費用的(de)(de)(de)影(ying)響。這(zhe)些(xie)(xie)非(fei)(fei)公(gong)(gong)(gong)(gong)認(ren)(ren)會(hui)(hui)(hui)計(ji)(ji)準(zhun)(zhun)(zhun)則(ze)(ze)(ze)財(cai)(cai)務(wu)(wu)(wu)衡量(liang)(liang)指標不符合(he)公(gong)(gong)(gong)(gong)認(ren)(ren)會(hui)(hui)(hui)計(ji)(ji)準(zhun)(zhun)(zhun)則(ze)(ze)(ze);不是公(gong)(gong)(gong)(gong)認(ren)(ren)會(hui)(hui)(hui)計(ji)(ji)準(zhun)(zhun)(zhun)則(ze)(ze)(ze)的(de)(de)(de)替(ti)代(dai)方法(fa);而且計(ji)(ji)算方法(fa)可能與其它公(gong)(gong)(gong)(gong)司公(gong)(gong)(gong)(gong)布的(de)(de)(de)非(fei)(fei)公(gong)(gong)(gong)(gong)認(ren)(ren)會(hui)(hui)(hui)計(ji)(ji)準(zhun)(zhun)(zhun)則(ze)(ze)(ze)財(cai)(cai)務(wu)(wu)(wu)信(xin)息(xi)不同。這(zhe)些(xie)(xie)結果只和(he)(he)相應公(gong)(gong)(gong)(gong)認(ren)(ren)會(hui)(hui)(hui)計(ji)(ji)準(zhun)(zhun)(zhun)則(ze)(ze)(ze)衡量(liang)(liang)指標一起用于(yu)評(ping)估(gu)(gu)我(wo)(wo)(wo)們(men)(men)的(de)(de)(de)經營(ying)(ying)業(ye)績。我(wo)(wo)(wo)們(men)(men)相信(xin),我(wo)(wo)(wo)們(men)(men)的(de)(de)(de)非(fei)(fei)公(gong)(gong)(gong)(gong)認(ren)(ren)會(hui)(hui)(hui)計(ji)(ji)準(zhun)(zhun)(zhun)則(ze)(ze)(ze)財(cai)(cai)務(wu)(wu)(wu)信(xin)息(xi)可為(wei)(wei)管(guan)(guan)理層(ceng)和(he)(he)投資(zi)者提(ti)供(gong)與財(cai)(cai)務(wu)(wu)(wu)和(he)(he)商業(ye)趨勢(與我(wo)(wo)(wo)們(men)(men)的(de)(de)(de)財(cai)(cai)務(wu)(wu)(wu)狀況(kuang)和(he)(he)經營(ying)(ying)業(ye)績相關)相關的(de)(de)(de)有用信(xin)息(xi),這(zhe)是因為(wei)(wei)非(fei)(fei)公(gong)(gong)(gong)(gong)認(ren)(ren)會(hui)(hui)(hui)計(ji)(ji)準(zhun)(zhun)(zhun)則(ze)(ze)(ze)衡量(liang)(liang)指標不包(bao)括管(guan)(guan)理層(ceng)認(ren)(ren)為(wei)(wei)不屬于(yu)Intermolecular核心經營(ying)(ying)業(ye)績的(de)(de)(de)費用。我(wo)(wo)(wo)們(men)(men)相信(xin),營(ying)(ying)收、凈(jing)(jing)營(ying)(ying)收成本、毛(mao)利潤、毛(mao)利率(lv)、經營(ying)(ying)(虧(kui)損(sun))盈余(yu)(yu)、凈(jing)(jing)(虧(kui)損(sun))盈余(yu)(yu)、每(mei)股(gu)(gu)盈余(yu)(yu)和(he)(he)每(mei)股(gu)(gu)凈(jing)(jing)(虧(kui)損(sun))盈余(yu)(yu)的(de)(de)(de)非(fei)(fei)公(gong)(gong)(gong)(gong)認(ren)(ren)會(hui)(hui)(hui)計(ji)(ji)準(zhun)(zhun)(zhun)則(ze)(ze)(ze)衡量(liang)(liang)指標(結合(he)我(wo)(wo)(wo)們(men)(men)根據公(gong)(gong)(gong)(gong)認(ren)(ren)會(hui)(hui)(hui)計(ji)(ji)準(zhun)(zhun)(zhun)則(ze)(ze)(ze)計(ji)(ji)算的(de)(de)(de)財(cai)(cai)務(wu)(wu)(wu)業(ye)績)可為(wei)(wei)投資(zi)者提(ti)供(gong)更多(duo)視角,并(bing)對我(wo)(wo)(wo)們(men)(men)經營(ying)(ying)業(ye)績現狀有更重(zhong)要的(de)(de)(de)了解。此外,管(guan)(guan)理層(ceng)使用這(zhe)些(xie)(xie)非(fei)(fei)公(gong)(gong)(gong)(gong)認(ren)(ren)會(hui)(hui)(hui)計(ji)(ji)準(zhun)(zhun)(zhun)則(ze)(ze)(ze)衡量(liang)(liang)指標查(cha)看并(bing)評(ping)估(gu)(gu)財(cai)(cai)務(wu)(wu)(wu)業(ye)績,來決定高管(guan)(guan)激(ji)勵薪酬(chou)(chou)以及規(gui)劃(hua)和(he)(he)預測(ce)未來業(ye)績。
Intermolecular, Inc. 簡明(ming)合(he)并運營數據表 (單位:千,每股數據除外,未經審計) |
||||||||
截至3月31日的3個月 |
||||||||
2018年 |
2017年 |
|||||||
營收 |
||||||||
項目營收 |
$ |
9,256 |
$ |
6,812 |
||||
許(xu)可和(he)使用費營收 |
419 |
3,133 |
||||||
總(zong)營(ying)收 |
9,675 |
9,945 |
||||||
營收(shou)成(cheng)本: |
||||||||
項目(mu)營收成本 |
3,375 |
2,697 |
||||||
許可和使用費營收成本 |
1 |
290 |
||||||
營收(shou)成(cheng)本總額 |
3,376 |
2,987 |
||||||
毛利(li)潤 |
6,299 |
6,958 |
||||||
運營費用: |
||||||||
研發(fa) |
4,032 |
7,108 |
||||||
銷售與營(ying)銷 |
796 |
1,481 |
||||||
一般與管理 |
2,286 |
3,008 |
||||||
重組費(fei)用(yong) |
— |
1,348 |
||||||
運營費用總額 |
7,114 |
12,945 |
||||||
運營虧損(sun) |
(815) |
(5,987) |
||||||
其它收入(費用(yong)): |
||||||||
利息(xi)收入(費(fei)用),凈(jing)值 |
106 |
55 |
||||||
其它收入(ru)(費用),凈值 |
87 |
97 |
||||||
其(qi)它(ta)收入(ru)(費(fei)用)總額,凈(jing)值 |
193 |
152 |
||||||
不計備付(fu)所得稅的(de)虧損 |
(622) |
(5,835) |
||||||
備付所得(de)稅 |
1 |
1 |
||||||
凈虧損 |
$ |
(623) |
$ |
(5,836) |
||||
基本和稀(xi)釋后每股凈虧損(sun) |
$ |
(0.01) |
$ |
(0.12) |
||||
用于計算(suan)基本和(he)稀釋后每股凈虧損的(de)加權平均股票數 |
49,581,927 |
49,519,251 |
Intermolecular, Inc. 簡明合并(bing)資產負債表 (單位:千,未經審計) |
||||||||
截至2018年3月31日 |
截至2017年12月31日 |
|||||||
資產 |
||||||||
流動(dong)資(zi)產: |
||||||||
現(xian)金(jin)和現(xian)金(jin)等價物 |
$ |
4,421 |
$ |
6,090 |
||||
短期投資 |
22,822 |
18,060 |
||||||
現金(jin)、現金(jin)等價物(wu)和短期(qi)投資(zi)總額(e) |
27,243 |
24,150 |
||||||
應收賬款 |
4,199 |
5,519 |
||||||
預付費用和其(qi)它流動(dong)資產(chan) |
959 |
1,069 |
||||||
流動資產總額 |
32,401 |
30,738 |
||||||
長期投(tou)資 |
— |
1,657 |
||||||
物料庫存 |
2,814 |
2,781 |
||||||
不(bu)動(dong)產(chan)和設備,凈值 |
4,940 |
5,913 |
||||||
無形(xing)資(zi)產,凈(jing)值 |
2,485 |
2,620 |
||||||
其它(ta)資產 |
589 |
600 |
||||||
資(zi)產總額 |
$ |
43,229 |
$ |
44,309 |
||||
負債及股東權益 |
||||||||
流(liu)動負債: |
||||||||
應付賬款 |
$ |
399 |
$ |
928 |
||||
應計負債 |
958 |
865 |
||||||
應計薪酬和員工福利(li) |
1,781 |
2,535 |
||||||
遞延營(ying)收 |
997 |
941 |
||||||
流動負(fu)債(zhai)總額 |
4,135 |
5,269 |
||||||
其它(ta)長期負債 |
2,906 |
2,967 |
||||||
負債總額 |
7,041 |
8,236 |
||||||
股東(dong)權益: |
||||||||
普通股 |
50 |
50 |
||||||
額外(wai)實收資(zi)本 |
215,082 |
214,796 |
||||||
累計其它綜合虧損(sun) |
(59) |
(35) |
||||||
累(lei)計赤字 |
(178,885) |
(178,738) |
||||||
股東權益總額 |
36,188 |
36,073 |
||||||
負債和(he)股東權(quan)益總(zong)額(e) |
$ |
43,229 |
$ |
44,309 |
Intermolecular, Inc. 簡明合并現金流報表 (單位:千,未經審計) |
||||||||
截至3月31日的3個月 |
||||||||
2018年 |
2017年 |
|||||||
來自經(jing)營(ying)活動(dong)的現金流(liu): |
||||||||
凈虧損(sun) |
$ |
(623) |
$ |
(5,836) |
||||
凈(jing)虧損與經營活動使用(yong)的(de)凈(jing)現金對照的(de)調整項: |
||||||||
折舊、攤銷(xiao)及增值 |
1,423 |
1,977 |
||||||
股票薪酬 |
270 |
656 |
||||||
不動產和設備處(chu)置(zhi)的(盈(ying)余)虧(kui)損 |
— |
(4) |
||||||
經(jing)營資(zi)產(chan)與負債變(bian)化: |
||||||||
應收(shou)賬款 |
1,796 |
1,248 |
||||||
預(yu)付費用和其它(ta)資(zi)產 |
121 |
476 |
||||||
物(wu)料(liao)庫存(cun) |
(69) |
78 |
||||||
應付賬款 |
(554) |
381 |
||||||
應計和其(qi)它負債 |
(730) |
1,394 |
||||||
遞延營收 |
56 |
183 |
||||||
經營活動使用的凈(jing)現金(jin) |
1,690 |
553 |
||||||
投資活動(dong)的現金(jin)流: |
||||||||
投資(zi)購買(mai) |
(6,252) |
(2,827) |
||||||
投(tou)資贖回 |
3,070 |
4,408 |
||||||
不動產和設備購買 |
(194) |
(264) |
||||||
設(she)備銷售收益 |
— |
7 |
||||||
投資(zi)活動提供(使(shi)用)的凈現金(jin) |
(3,376) |
1,324 |
||||||
金融活(huo)動(dong)的(de)現金流: |
||||||||
資本租賃付款 |
— |
(5) |
||||||
行使普通股期權(quan)的收益 |
17 |
— |
||||||
金(jin)(jin)融活動提供(使(shi)用)的凈現金(jin)(jin) |
17 |
(5) |
||||||
現金(jin)和現金(jin)等(deng)價物的(de)凈增長(chang)(減少) |
(1,669) |
1,872 |
||||||
期初的現(xian)金(jin)和現(xian)金(jin)等價物 |
6,090 |
5,759 |
||||||
期末的現金(jin)和現金(jin)等價物 |
$ |
4,421 |
$ |
7,631 |
Intermolecular, Inc. 公認會計準(zhun)則(ze)和非公認會計準(zhun)則(ze)財務(wu)衡(heng)量(liang)指標的對(dui)照表 (單位:千,每股數據和百分比除外,未經審計) |
||||||||
截至3月31日的3個月 |
||||||||
2018年 |
2017年 |
|||||||
按GAAP計算的凈營(ying)收成本 |
$ |
3,376 |
$ |
2,987 |
||||
股票薪酬費用(yong) (a) |
(53) |
(65) |
||||||
按非GAAP計算的凈營收(shou)成(cheng)本 |
$ |
3,323 |
$ |
2,922 |
||||
按GAAP計(ji)算的(de)的(de)毛利潤 |
$ |
6,299 |
$ |
6,958 |
||||
股票薪酬費用(yong) (a) |
53 |
65 |
||||||
按非GAAP計算的(de)毛(mao)利潤 |
$ |
6,352 |
$ |
7,023 |
||||
占凈(jing)營收的百(bai)分比: |
||||||||
按GAAP計算的毛利潤率 |
65.1% |
70.0% |
||||||
按非GAAP計算(suan)的毛利潤率 |
65.7% |
70.6% |
||||||
按(an)GAAP計算的經(jing)營虧損 |
$ |
(815) |
$ |
(5,987) |
||||
股票薪酬費用 (a): |
||||||||
-凈營(ying)收成本 |
53 |
65 |
||||||
-研發 |
55 |
182 |
||||||
-銷(xiao)售與(yu)營(ying)銷(xiao) |
30 |
59 |
||||||
-一般與管理 |
132 |
350 |
||||||
按(an)非GAAP計算的經營虧損 |
$ |
(545) |
$ |
(5,331) |
||||
按(an)GAAP計算的凈(jing)虧損 |
$ |
(623) |
$ |
(5,836) |
||||
股(gu)票薪酬費用 (a) |
270 |
656 |
||||||
按(an)非GAAP計算的凈虧損 |
$ |
(353) |
$ |
(5,180) |
||||
按(an)GAAP計算的凈(jing)虧損(sun) |
$ |
(623) |
$ |
(5,836) |
||||
利息收入(費用),凈值 |
106 |
55 |
||||||
備付(fu)稅收(shou) |
1 |
1 |
||||||
折舊、攤銷、減損與增值 |
1,423 |
1,977 |
||||||
重組(zu)費用(yong) (b) |
— |
1,348 |
||||||
股票薪酬費用 (a) |
270 |
656 |
||||||
調整后的EBITDA |
$ |
965 |
$ |
(1,909) |
||||
用于計算按GAAP計算的基本(ben)和稀(xi)釋后每(mei)股盈(ying)余的股票 |
49,582 |
49,519 |
||||||
按GAAP計算的(de)每(mei)股(gu)盈余(yu): |
||||||||
基本(ben)和(he)稀釋后每(mei)股凈虧損 |
$ |
(0.01) |
$ |
(0.12) |
||||
用于計算按非GAAP計算的(de)基本(ben)和(he)稀釋后每股盈(ying)余的(de)股票 |
49,582 |
49,519 |
||||||
按非GAAP計算的(de)每股盈余: |
||||||||
基(ji)本和稀釋后每股凈(jing)虧損 |
$ |
(0.01) |
$ |
(0.10) |
||||
基于股票的(de)薪酬(chou)反映的(de)是與股票獎勵(li)相關(guan)的(de)記錄費用。評估持續經(jing)營(ying)業績(ji)時,該公司并未考慮這一項,因為管理層認(ren)為這樣可使其對核心(xin)經(jing)營(ying)業績(ji)有重要的(de)了解。 |
||||||||
(b) |
員(yuan)工(gong)總人數(shu)減少帶(dai)來的(de)重組費(fei)用(yong)主要由員(yuan)工(gong)遣散(san)費(fei)和(he)福利成本組成。 |
Intermolecular, Inc. 2018年第二(er)季度業績展(zhan)望 按GAAP計(ji)算的(de)凈(jing)(jing)盈余/虧損(sun)與按非GAAP計(ji)算的(de)凈(jing)(jing)盈余的(de)對照(zhao)表 (單位:千,每股數據(ju)除外,未(wei)經審計) |
||
按(an)GAAP計(ji)算的凈盈余/虧(kui)損范圍(wei) |
$(300) - $300 |
|
基于股票的薪酬 |
$300 - $300 |
|
按非(fei)GAAP計算的凈盈余范圍 |
$0 - $600 |
|
按GAAP和非GAAP計算的稀釋后股票 |
49,600 |
|
按GAAP計算(suan)的(de)每股凈(jing)盈余/虧(kui)損(sun)范圍 |
$(0.01) - $0.01 |
|
按非GAAP計算(suan)的(de)每股(gu)凈盈余(yu)范(fan)圍 |
$0.00 - $0.01 |
企業聯系人:
Bill Roeschlein
Intermolecular, Inc.
首席財務官
電郵:
電話:(408) 582-5415
投資者聯系人:
Matt Glover或Najim Mostamand, 特許金融分析師
Liolios Group, Inc.
電郵:
電話:(949) 574-3860
圖標 -